Suven Pharmaceuticals Ltd
Suven Pharma is in the business of Contract development & manufacturing organisation (CDMO), catering to the needs of global Pharma Industry.
- Market Cap ₹ 12,430 Cr.
- Current Price ₹ 488
- High / Low ₹ 632 / 388
- Stock P/E 28.8
- Book Value ₹ 59.0
- Dividend Yield 0.41 %
- ROCE 40.8 %
- ROE 29.8 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 34.9%
- Company has been maintaining a healthy dividend payout of 20.7%
Cons
- Stock is trading at 8.31 times its book value
- Debtor days have increased from 51.2 to 65.4 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|
378 | 834 | 1,010 | 1,320 | 1,373 | |
206 | 449 | 567 | 738 | 779 | |
Operating Profit | 172 | 385 | 443 | 582 | 594 |
OPM % | 45% | 46% | 44% | 44% | 43% |
1 | 66 | 68 | 133 | 104 | |
Interest | 3 | 23 | 12 | 9 | 5 |
Depreciation | 12 | 24 | 32 | 39 | 44 |
Profit before tax | 158 | 405 | 468 | 668 | 648 |
Tax % | 31% | 22% | 23% | 32% | |
Net Profit | 109 | 317 | 362 | 454 | 431 |
EPS in Rs | 5,463.50 | 12.45 | 14.23 | 17.83 | 16.94 |
Dividend Payout % | 0% | 20% | 14% | 28% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 52% |
TTM: | 25% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 55% |
TTM: | 8% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -11% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 35% |
Last Year: | 30% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|
13 | 13 | 25 | 25 | 25 | |
Reserves | 578 | 832 | 1,155 | 1,502 | 1,478 |
83 | 186 | 143 | 97 | 91 | |
123 | 142 | 151 | 205 | 211 | |
Total Liabilities | 783 | 1,173 | 1,474 | 1,830 | 1,806 |
271 | 357 | 441 | 534 | 670 | |
CWIP | 111 | 102 | 96 | 30 | 87 |
Investments | 7 | 338 | 542 | 598 | 444 |
394 | 376 | 395 | 667 | 604 | |
Total Assets | 783 | 1,173 | 1,474 | 1,830 | 1,806 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|
50 | 407 | 383 | 330 | |
-65 | -413 | -311 | -136 | |
26 | 7 | -76 | -156 | |
Net Cash Flow | 11 | 1 | -5 | 37 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|
Debtor Days | 142 | 51 | 37 | 65 |
Inventory Days | 556 | 278 | 243 | 259 |
Days Payable | 190 | 113 | 100 | 97 |
Cash Conversion Cycle | 509 | 217 | 180 | 228 |
Working Capital Days | 285 | 105 | 95 | 126 |
ROCE % | 49% | 40% | 41% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Tuesday, February 7, 2023 at 12:00 …
- Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Monday, The February 6, 2023 2d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 29 Jan
-
Announcement under Regulation 30 (LODR)-Credit Rating
16 Jan - The CRISIL has assigned the following ratings to the Bank facilities of our Company as per communication received on January 16, 2023. Facilities Rating Long-term …
-
Draft Letter of Offer
9 Jan - Kotak Mahindra Capital Company Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Draft Letter of Offer for the attention of …
Annual reports
Concalls
-
Dec 2022TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022Transcript PPT
-
Jun 2022TranscriptPPT
-
May 2022Transcript PPT
-
May 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Dec 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptPPT
Business Segments
CDMO (Development projects and Commercial supplies)
SPL engages in NCE molecule development and supply of intermediates. This is a high-value-add, high-margin business. SPL supplies intermediates for four molecules addressing rheumatoid arthritis, diabetes, depression and women’s health[1]. This segment makes up 78% of revenues. The company has a strong order book with new clients being consistently added. Most clients are the Big Pharma companies in Europe and the US. The company is looking to shift from Intermediate to API manufacturing and is in discussion with clients regarding this. The company has stated that it has the facilities for API manufacturing.[2]